TORONTO, ONTARIO--(Marketwire - Sept. 10, 2012) - Abattis Biologix Corporation has announced a name change to Abattis Bioceuticals Corp. and the consolidation of its common shares on the basis of one (1) new post-consolidation common share for each five (5) pre-consolidation common shares effective September 13, 2012. Any fractional shares resulting from the consolidation comprising less than half common share will be rounded down to the nearest whole number, and any fractional shares comprising greater than or equal to half common share will be converted into one whole common share. As a result the outstanding common shares of the company will be reduced to approximately 12,353,564.
The common shares of Abattis Bioceuticals will begin trading on a consolidated basis on Tuesday, September 11, 2012.
Please note the company will continue to trade under the symbol "FLU". All open orders will be cancelled at the end of business on September 10, 2012. CNSX Dealers are reminded to re-enter their orders taking into account the share consolidation.
Listing and disclosure documents for Abattis Bioceuticals are available in the Listings Disclosure Hall.
Trading Date: Tuesday, September 11, 2012
NEW CUSIP: 00258G 10 3
NEW ISIN: CA 00258G10 3 7